Article Information
History
- November 12, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Michael P. Coryell, PhDa,
- Mikhail Iakiviak, PhDb,
- Nicole Pereira, PhDb,
- Pallavi P. Murugkar, PhDb,
- Jason Rippe, JDc,
- David B. Williams, BSc,
- Jessica L. Hastie, PhDa,
- Rosa L. Sava, BSa,
- Christopher Z. Lien, M.S.e,
- Tony T. Wang, PhDe,
- William J. Muller, MDc,d,
- Michael A. Fischbach, PhDb and
- Paul E. Carlson Jr., PhDa,*
- aDivision of Bacterial, Parasitic and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA
- bDepartment of Bioengineering and ChEM-H, Stanford University, 290 Jane Stanford Way, Stanford, CA 94305, USA
- cDivision of Infectious Diseases, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital, 225 E. Chicago Ave, Chicago, Illinois 60611
- dNorthwestern University Feinberg School of Medicine, 225 E. Chicago Ave, Chicago, Illinois 60611
- eDivision of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue Silver Spring, Maryland, 20993, USA
- ↵*Corresponding author:
Paul E. Carlson Jr. Division of Bacterial, Parasitic and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration,10903 New Hampshire Avenue, Silver Spring, Maryland 20993, USA. Tel: 240-402-4090; E-mail: paul.carlson{at}fda.hhs.gov